Universal Health Services UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Really well. That is great. That is great. All right. I think we are ready to get going. See if I am hooked up here. We are very happy to have Universal Health Services next up. Steve Filton, Chief Financial Officer, and Darren Lehrich, Vice President of Investor Relations. Just to maybe level set and kick it off, we are 10 months into the year. What have been some of the positives? What have been some of the challenges? Where have there been surprises, you think, Steve?
Yeah, I mean, going into the year, there were a couple of sort of known headwinds. I think primarily for us, the anticipated decline in exchange patients, the California staffing ratios for behavioral facilities. We included those headwinds in our guidance. The year started off a little bit slow. Volumes in Q1 were kind of on the softer side, weather issues around the country. But I think as the year went on, volumes began to recover, and I think we have been pretty pleased with volumes in both segments in the third quarter. I think sort of the biggest headwind that kind of developed during the year was the underperformance of a couple of our de novo facilities, a newer hospital in the Washington, D.C. market that opened last year, and then a hospital, quite frankly, right in this market that opened earlier in the summer.
A behavioral hospital in the San Antonio, Texas market that lost its Medicare certification earlier in the year. Those three hospitals together have sort of, I think, had $80 million-$100 million of unanticipated, or to some degree unanticipated losses for the year. Slower ramp-ups at the de novos. Obviously, the San Antonio losses were unanticipated. I think that has been the biggest hurdle. I mean, I think the nice thing is that with the good volumes, I think with the solid expense control that we have generally been experiencing, the underperformance of those facilities sort of creates a tailwind going into next year, and so we are looking forward to that.
Yeah, that good segue into the next question I was thinking about was, we are at this point in the year starting to think about headwinds and tailwinds next year beyond just the normal business progression that you always expect. What would you single out? How would you describe some of the headwinds and tailwinds that we should take into account as we are moving into next year?
Yeah, I mean, the primary tailwind is the continued improvement of the three facilities that I enumerated. We've also got the Talkspace acquisition that we completed in August, that I think we believe is going to ultimately be a significant accelerant to outpatient growth in our behavioral division. In this first year of ownership, through the middle of next year, likely having, I think, a modestly accretive effect. But after that, I think really starting to get some traction in helping us build our outpatient volumes on the behavioral side. I think we've got pretty solid Medicare rate increases in the coming year, so that's a plus.
The biggest, I think, headwind going into next year, and we talked about this on our Q3 call, is we've got about $175 million-$200 million of out-of-period DPP, or Directed Payment Program, Medicaid supplemental payments that we received in 2026 that will not recur in 2027. Offsetting that, hopefully, will be a Florida DPP program for both 2026 and 2027 that has not yet been approved and we have not yet recognized, but would hope to do so at some point over the next several months or quarters.
Yeah. Then maybe just to put a finer point on those facilities, the three that you've mentioned that have been a drag, how much could they represent in possible tailwind next year?
Yeah, so I think the way we framed it, A.J., is that to date, or through the third quarter, they've contributed about $80 million-$100 million of losses this year, and that our expectation is that a meaningful portion of those losses will be made up next year and should create a tailwind. Again, I think both Cedar Hill, which is the D.C. hospital, and Alan B. Miller Medical Center, which is the hospital in this market, continue to improve. The hospital in this market opened in the beginning of the summer, not the ideal time to open a hospital in the South Florida market, but has been improving each month, volumes increasing every month, losses declining. And now as we move into the season here in Florida, looking forward to a strong season and ramping up during that time.
As far as the San Antonio facility, it continues to operate, albeit with a small number of patients. We are going through the steps necessary to get recertified. So far, we have been completing those steps without any issues. The hope is that at some point in 2027, we get recertified, we ramp up, and get back to. This was one of our larger, more profitable facilities in the behavioral division. Again, looking forward to that, although the precise timing is difficult to say. Hopefully, by the time we give our guidance at the end of February for 2027, we will have a little bit more precise view of how that facility will ramp up.
AJ, I would just add that when you think about those three facilities, we are obviously talking about 2027 and recovering some of that $80 million-$100 million of losses that we are incurring in 2026. But you should also think about those three facilities as embedded growth, looking out beyond 2027. $80 million-$100 million really is just the level to which they get back to break even.
Break even. Or reach the break-even level.
Obviously, we have longer-term views on success of those facilities and the recovery of those facilities.
To that end, have you guys put any parameters around what a normalized earnings run rate from those three, what embedded earnings might represent?
No, look, I think characterized in the San Antonio facility, we've disclosed in our SEC filings and what the facility made in 2025, which was what, $25 million-$30 million range. There's no reason in my mind that the facility in this market shouldn't get up to divisional averages within the first 18 to 24 of margins, within the first 18 to 24 months of operation. Cedar Hill in Washington, D.C. is a little bit different. We've described the arrangement. That's really a partnership with the District of Columbia. They built that hospital really because they felt that that part of the district, Ward 7 and 8, to be technical, had really been underserved from a healthcare perspective for years. Given their long relationship with us at GW Hospital in the market, they built that hospital. They spent the $300 million or $400 million to build it.
We own and operate it. When we get to, or we don't need to get to the same level of absolute earnings and absolute margins that we would at a hospital that we built and invested in. Our rate of return hurdle is going to be much lower because we've got much less invested in that facility.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
